However, there is a discrepancy in which several studies have shown that SFRP2 is an agonist (rather than an antagonist) of β-catenin [20]–[24] suggesting the reverse: that SFRP2 may promote tumor growth. The gene discussed is SFRP2; the disease is neoplasm.